- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04435600
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms (OptIMMize-1)
A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants with moderate to severe plaque psoriasis. This study will assess the change in disease symptoms.
Risankizumab is a drug being studied for the treatment for plaque psoriasis in pediatric participants. This study has 4 parts.
Part 1: Participants aged 12 < 18 will receive a fixed dose of risankizumab. Part 2: Participants aged 12 < 18 will receive;
- Period A: Risankizumab or ustekinumab based on body weight followed by;
- Period B: Risankizumab or no treatment.
- Period C: Re-treatment with risankizumab (if needed).
Part 3: Participants aged 6 < 12 will receive risankizumab based on body weight.
Part 4: Participants aged 6 < 12 will receive risankizumab based on body weight (Japan only: Participants aged 12 > 18 will receive risankizumab based on body weight).
Around 132 participants will be enrolled in approximately 50 sites worldwide.
Risankizumab and ustekinumab are given as a subcutaneous (under the skin) injection.
Parts 1, 3, and 4: Risankizumab for 40 weeks with a follow-up call 20 weeks later for a study duration of approximately 65 weeks.
Part 2:
- Period A: Risankizumab or ustekinumab for 16 weeks.
- Period B: Risankizumab or no treatment for 36 weeks.
- Period C: Re-treatment with risankizumab for 16 weeks. Follow-up call 20 weeks later for a study duration of approximately 81 weeks. Participants from each Part who meet eligibility criteria for an open-label extension (OLE) study may continue on risankizumab for 216 additional weeks.
There may be a higher burden for study participants compared to standard treatment. Participants will attend monthly visits and medical assessments will check the effect of treatment through blood tests, questionnaires, and checking for side effects.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: ABBVIE CALL CENTER
- Phone Number: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2J 7E1
- Dermatology Research Institute Inc. /ID# 226172
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1A 4Y3
- Karma Clinical Trials /ID# 226177
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children /ID# 226167
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- CHU Sainte-Justine /ID# 226170
-
-
-
-
-
Bad Bentheim, Germany, 48455
- Fachklinik Bad Bentheim /ID# 226014
-
Bonn, Germany, 53127
- Universitaetsklinikum Bonn /ID# 228880
-
Dresden, Germany, 01307
- Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 228881
-
Mainz, Germany, 55131
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 225987
-
-
Nordrhein-Westfalen
-
Muenster, Nordrhein-Westfalen, Germany, 48149
- Universitaetsklinikum Muenster /ID# 225988
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
- Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 226013
-
-
-
-
Aichi
-
Nagoya shi, Aichi, Japan, 467-8602
- Nagoya City University Hospital /ID# 230830
-
-
Hiroshima
-
Hiroshima-shi, Hiroshima, Japan, 734-8551
- Hiroshima University Hospital /ID# 256162
-
-
Mie
-
Tsu-shi, Mie, Japan, 514-8507
- Mie University Hospital /ID# 230836
-
-
Osaka
-
Hirakata-shi, Osaka, Japan, 573-1191
- Kansai Medical University Hospital /ID# 231215
-
-
Tokyo
-
Itabashi-ku, Tokyo, Japan, 173-8606
- Teikyo University Hospital /ID# 255188
-
Shinjuku-ku, Tokyo, Japan, 160-0023
- Tokyo Medical University Hospital /ID# 230575
-
-
-
-
Lodzkie
-
Lodz, Lodzkie, Poland, 90-265
- Dermed Centrum Medyczne Sp. z o.o /ID# 226062
-
Lodz, Lodzkie, Poland, 90-436
- Dermoklinika Centrum Medyczne s.c. /ID# 226063
-
-
Mazowieckie
-
Warszawa, Mazowieckie, Poland, 01-817
- High-Med Przychodnia Specjalistyczna /ID# 226060
-
-
Podkarpackie
-
Rzeszow, Podkarpackie, Poland, 35-055
- Uniwersytecki Szpital Kliniczny im. F. Chopina w Rzeszowie /ID# 226116
-
-
Pomorskie
-
Gdansk, Pomorskie, Poland, 80-546
- Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 228252
-
-
-
-
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon /ID# 225721
-
Madrid, Spain, 28031
- Hospital Universitario Infanta Leonor /ID# 225720
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre /ID# 227860
-
Pontevedra, Spain, 36071
- Complejo Hospitalario Universitario de Pontevedra /ID# 226061
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spain, 08950
- Hospital Sant Joan de Deu /ID# 225722
-
-
-
-
-
London, United Kingdom, SW10 9NH
- Chelsea and Westminster Hospital NHS Foundation Trust /ID# 227231
-
Plymouth, United Kingdom, PL6 5FP
- University Hospital Plymouth NHS Trust /ID# 227230
-
-
Devon
-
Exeter, Devon, United Kingdom, EX2 5DW
- Royal Devon University Healthcare NHS Foundation Trust /ID# 228078
-
-
London, City Of
-
London, London, City Of, United Kingdom, SE1 9RT
- Guys and St Thomas NHS Foundation Trust /ID# 227224
-
-
Scotland
-
Glasgow, Scotland, United Kingdom, G12 0XH
- NHS Greater Glasgow and Clyde /ID# 227226
-
-
Surrey
-
Camberley, Surrey, United Kingdom, GU16 7UJ
- Frimley Health NHS Foundation Trust /ID# 229525
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- UAB Department of Dermatology /ID# 218834
-
-
California
-
Fountain Valley, California, United States, 92708-3701
- First OC Dermatology Research Inc /ID# 217733
-
Sacramento, California, United States, 95815
- Integrative Skin Science and Research /ID# 221741
-
San Diego, California, United States, 92123
- University of California San Diego - Rady Children's Hospital San Diego /ID# 217906
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33316-1952
- Rybear, Inc /ID# 223164
-
Jacksonville, Florida, United States, 32256
- Solutions Through Adv Rch /ID# 217936
-
Saint Petersburg, Florida, United States, 33709-1405
- Olympian Clinical Research- St. Petersburg /ID# 217941
-
Tampa, Florida, United States, 33607
- Advanced Clinical Research Institute /ID# 222706
-
-
Illinois
-
Darien, Illinois, United States, 60561
- University Dermatology and Vein Clinic, LLC /ID# 222778
-
Rolling Meadows, Illinois, United States, 60008
- Duplicate_Arlington Dermatology /ID# 217472
-
-
Nevada
-
Reno, Nevada, United States, 89052
- Skin Cancer and Dermatology Institute (SCDI) /ID# 221738
-
-
New York
-
Kew Gardens, New York, United States, 11415
- Forest Hills Dermatology Group /ID# 227941
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Univ Hosp Cleveland /ID# 228483
-
Columbus, Ohio, United States, 43210
- The Ohio State University /ID# 217808
-
Mayfield Heights, Ohio, United States, 44124-4005
- Apex Dermatology & Skin Surgery Center /ID# 228537
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136-7049
- Vital Prospects Clinical Research Institute, PC /ID# 217960
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina /ID# 217735
-
-
Texas
-
Arlington, Texas, United States, 76011
- Arlington Research Center, Inc /ID# 217471
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- West Virginia University Hospitals /ID# 228352
-
-
Wisconsin
-
Kenosha, Wisconsin, United States, 53144-1782
- Clinical Investigation Specialist, Inc - Kenosha /ID# 223161
-
Milwaukee, Wisconsin, United States, 53226-3522
- Medical College of Wisconsin /ID# 240005
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of chronic plaque psoriasis for at least 6 months before the Baseline Visit.
- Stable severe or moderate to severe plaque psoriasis as defined in each study part by body surface area (BSA) psoriasis involvement and scores on the Psoriasis Area and Severity Index (PASI) and Static Physician Global Assessment (sPGA).
- Candidate for systemic therapy as assessed by the investigator and meet the disease activity criteria at both the Screening and Baseline Visits per the protocol.
Exclusion Criteria:
- Concurrent clinically significant medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the participant's participation in this study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk by participating in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Risankizumab Dose A
Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.
|
Subcutaneous Injection
Other Names:
|
Experimental: Part 2: Ustekinumab Dose A/B/C then Risankizumab Dose A/B
Participants age 12 to less than 18 will receive: Period A: Ustekinumab Dose A, Dose B, or Dose C based on body weight for 16 weeks (at Week 0 and Week 4). Period B: Risankizumab Dose A or B based on body weight for 24 weeks. |
Subcutaneous Injection
Other Names:
Subcutaneous Injection
|
Experimental: Part 2: Risankizumab Dose A/B
Participants age 12 to less than 18 will receive: Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4). Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare. Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4). |
Subcutaneous Injection
Other Names:
|
Experimental: Part 3: Risankizumab Dose A/B
Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
|
Subcutaneous Injection
Other Names:
|
Experimental: Part 4: Risankizumab Dose A/B
Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks (Japan only: participants age 12 to less than 18 years will be included).
|
Subcutaneous Injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI)
Time Frame: Baseline (Week 0) to Week 16 of each part of the study (Parts 1-4)
|
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities).
Scores range from 0 to 72, with the highest score representing complete erythroderma of the severest degree.
|
Baseline (Week 0) to Week 16 of each part of the study (Parts 1-4)
|
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) Clear or Almost Clear
Time Frame: At Week 16 of each part of the study (Parts 1-4)
|
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.
Scores range from 0 (clear) to 4 (severe).
|
At Week 16 of each part of the study (Parts 1-4)
|
US Only: Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) Clear or Almost Clear and with at least 2 grade improvement from baseline
Time Frame: At Week 16 of each part of the study (Parts 1-4)
|
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.
Scores range from 0 (clear) to 4 (severe).
|
At Week 16 of each part of the study (Parts 1-4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)
Time Frame: Baseline (Week 0) to Week 16 of each part of the study (Parts 1-4)
|
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities).
Scores range from 0 to 72, with the highest score representing complete erythroderma of the severest degree.
|
Baseline (Week 0) to Week 16 of each part of the study (Parts 1-4)
|
Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)
Time Frame: Baseline (Week 0) to Week 16 of each part of the study (Parts 1-4)
|
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities).
Scores range from 0 to 72, with the highest score representing complete erythroderma of the severest degree.
|
Baseline (Week 0) to Week 16 of each part of the study (Parts 1-4)
|
Part 2 (Period C): Percentage of Participants sPGA Clear or Almost Clear
Time Frame: Baseline (Week 0) to Week 16 upon start of re-treatment in Part 2 (Period C)
|
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.
Scores range from 0 (clear) to 4 (severe).
|
Baseline (Week 0) to Week 16 upon start of re-treatment in Part 2 (Period C)
|
Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)
Time Frame: Baseline (Week 0) to Week 16 of each part of the study (Parts 1-4)
|
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities).
Scores range from 0 to 72, with the highest score representing complete erythroderma of the severest degree.
|
Baseline (Week 0) to Week 16 of each part of the study (Parts 1-4)
|
Part 2 (Period C): Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)
Time Frame: Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities).
Scores range from 0 to 72, with the highest score representing complete erythroderma of the severest degree.
|
Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
Part 2 (Period C): Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)
Time Frame: Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities).
Scores range from 0 to 72, with the highest score representing complete erythroderma of the severest degree.
|
Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
Part 2 (Period C): Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)
Time Frame: Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities).
Scores range from 0 to 72, with the highest score representing complete erythroderma of the severest degree.
|
Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
Part 2 (Period C): Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI)
Time Frame: Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities).
Scores range from 0 to 72, with the highest score representing complete erythroderma of the severest degree.
|
Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
Part 2 (Period A): Change in Children's Dermatology Life Quality Index (CDLQI)
Time Frame: Baseline (Week 0) to Week 16 in Part 2 (Period A)
|
The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL).
|
Baseline (Week 0) to Week 16 in Part 2 (Period A)
|
Part 2 (Period C): Change in CDLQI
Time Frame: Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on QOL.
|
Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
Part 2 (Period A): Change in Family Dermatology Life Quality Index (FDLQI)
Time Frame: Baseline (Week 0) to Week 16 in Part 2 (Period A)
|
The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on QOL of family members.
|
Baseline (Week 0) to Week 16 in Part 2 (Period A)
|
Part 2 (Period C): Change in FDLQI
Time Frame: Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on QOL of family members.
|
Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
Part 2 (Period C): Change in Itch NRS
Time Frame: Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
The itch NRS is an 11-points scale that subjects will complete to describe the intensity of their itch using a 24-hour recall period.
The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable."
|
Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
Part 2 (Period C): US Only: Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) Clear or Almost Clear and with at least 2 grade improvement from baseline
Time Frame: Baseline (Week 0) to Week 16 upon start of re-treatment in Part 2 (Period C)
|
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions.
Scores range from 0 (clear) to 4 (severe).
|
Baseline (Week 0) to Week 16 upon start of re-treatment in Part 2 (Period C)
|
Part 2 (Period C): Change in Itch Numerical Rating Scale (Itch NRS)
Time Frame: Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
The itch NRS is an 11-points scale that subjects will complete to describe the intensity of their itch using a 24-hour recall period.
The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable."
|
Baseline (Week 0) to Week 16 upon starting re-treatment in Part 2 (Period C)
|
Part 2 (Period A): Percentage of Participants Achieving > = 4-point Improvement in the Itch Numerical Rating Scale (in Participants with Baseline Score > = 4) at Each Study Visit
Time Frame: Baseline (Week 0) to Week 16 in Part 2 (Period A)
|
The itch NRS is an 11-points scale that subjects will complete to describe the intensity of their itch using a 24-hour recall period.
The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable."
|
Baseline (Week 0) to Week 16 in Part 2 (Period A)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M19-977
- 2023-504156-10-00 (Other Identifier: EU CT)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Risankizumab
-
Shaare Zedek Medical CenterNot yet recruitingCrohn Disease
-
AbbVieActive, not recruiting
-
AbbVieActive, not recruitingCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
-
AbbVieCompleted
-
AbbViePPDRecruitingPlaque Psoriasis | Crohn Disease | Psoriatic Arthritis | Other Conditions for Which Risankizumab is an FDA-approved TreatmentUnited States
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
-
AbbVieCompletedUlcerative Colitis (UC)United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
-
AbbVieCompleted
-
Janssen Research & Development, LLCTerminatedHealthy | Arthritis, PsoriaticAustria
-
AbbVieCompletedHealthy VolunteersUnited States